Initial Data of LUCIDITY Study
Recent News
We’re pleased to announce the Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed acceptance of the UK Marketing Authorisation Application (MAA) for hydromethylthionine mesylate (HMTM), a 4 mg oral tablet for the treatment of mild cognitive impairment (MCI-AD) and mild to moderate Alzheimer’s disease.
Jul 29, 2024
TauRx Pharmaceuticals Ltd, a global leader in tau-based research in Alzheimer’s disease (AD), has announced the submission of a UK Marketing Authorisation Application (MAA) for hydromethylthionine mesylate (HMTM) for treatment of mild cognitive impairment (MCI-AD) and mild to moderate stages of dementia due to Alzheimer’s disease.
Jul 01, 2024
TauRx Pharmaceuticals Ltd., a global leader in tau-based research in Alzheimer’s disease (AD), presented the 24-month data from its Phase 3 LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference in Lisbon, Portugal.
Mar 07, 2024
Today is the United Nations International Day of Women and Girls in Science. The day is marked every year on February 11 to ensure equal access and participation for women and girls in science.
Feb 11, 2024